vs
ANI PHARMACEUTICALS INC（ANIP）とRegency Centers（REG）の財務データ比較。上の社名をクリックして会社を切り替えられます
Regency Centersの直近四半期売上が大きい（$404.2M vs $247.1M、ANI PHARMACEUTICALS INCの約1.6倍）。Regency Centersの純利益率が高く（50.1% vs 11.1%、差は39.0%）。ANI PHARMACEUTICALS INCの前年同期比売上増加率が高い（29.6% vs 8.5%）。過去8四半期でANI PHARMACEUTICALS INCの売上複合成長率が高い（34.1% vs 5.4%）
ANIファーマシューティカルズは米国に本社を置く特殊製薬会社で、後発医薬品とブランド処方薬の研究開発・製造・販売を行っています。主力製品分野は皮膚科、腫瘍、中枢神経系治療、感染症対策で、主に米国内の医療機関、調剤薬局、患者を対象としています。
Regency Centers Corporationはフロリダ州ジャクソンビルに本拠を置く不動産投資信託で、食料品店を中心テナントとするショッピングセンターの最大手運営企業の1つです。2020年10月21日時点で415物件、計5600万平方フィートのスペースを所有し、代表的な資産にSerramonte CenterやVillage Districtの30%持分があります。
ANIP vs REG — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $247.1M | $404.2M |
| 純利益 | $27.5M | $202.5M |
| 粗利率 | — | — |
| 営業利益率 | 14.1% | 71.0% |
| 純利益率 | 11.1% | 50.1% |
| 売上前年比 | 29.6% | 8.5% |
| 純利益前年比 | 367.5% | 134.1% |
| EPS（希薄化後） | $1.14 | — |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $247.1M | $404.2M | ||
| Q3 25 | $227.8M | $387.6M | ||
| Q2 25 | $211.4M | $380.8M | ||
| Q1 25 | $197.1M | $380.9M | ||
| Q4 24 | $190.6M | $372.5M | ||
| Q3 24 | $148.3M | $360.3M | ||
| Q2 24 | $138.0M | $357.3M | ||
| Q1 24 | $137.4M | $363.9M |
| Q4 25 | $27.5M | $202.5M | ||
| Q3 25 | $26.6M | $109.4M | ||
| Q2 25 | $8.5M | $106.0M | ||
| Q1 25 | $15.7M | $109.6M | ||
| Q4 24 | $-10.3M | $86.5M | ||
| Q3 24 | $-24.2M | $101.5M | ||
| Q2 24 | $-2.3M | $102.7M | ||
| Q1 24 | $18.2M | $109.8M |
| Q4 25 | 14.1% | 71.0% | ||
| Q3 25 | 15.9% | 72.7% | ||
| Q2 25 | 6.6% | 73.8% | ||
| Q1 25 | 13.3% | 71.8% | ||
| Q4 24 | -2.3% | 71.1% | ||
| Q3 24 | -13.8% | 72.5% | ||
| Q2 24 | 3.7% | 72.3% | ||
| Q1 24 | 14.8% | 72.3% |
| Q4 25 | 11.1% | 50.1% | ||
| Q3 25 | 11.7% | 28.2% | ||
| Q2 25 | 4.0% | 27.8% | ||
| Q1 25 | 8.0% | 28.8% | ||
| Q4 24 | -5.4% | 23.2% | ||
| Q3 24 | -16.3% | 28.2% | ||
| Q2 24 | -1.7% | 28.7% | ||
| Q1 24 | 13.2% | 30.2% |
| Q4 25 | $1.14 | — | ||
| Q3 25 | $1.13 | — | ||
| Q2 25 | $0.36 | — | ||
| Q1 25 | $0.69 | — | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $-1.27 | — | ||
| Q2 24 | $-0.14 | — | ||
| Q1 24 | $0.82 | — |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $285.6M | — |
| 総負債低いほど良い | — | $4.7B |
| 株主資本純資産 | $540.7M | $6.9B |
| 総資産 | $1.4B | $13.0B |
| 負債/資本比率低いほどレバレッジが低い | — | 0.69× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $285.6M | — | ||
| Q3 25 | $262.6M | — | ||
| Q2 25 | $217.8M | — | ||
| Q1 25 | $149.8M | — | ||
| Q4 24 | $144.9M | — | ||
| Q3 24 | $145.0M | — | ||
| Q2 24 | $240.1M | — | ||
| Q1 24 | $228.6M | — |
| Q4 25 | — | $4.7B | ||
| Q3 25 | — | $4.9B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $4.6B | ||
| Q4 24 | — | $4.4B | ||
| Q3 24 | — | $4.4B | ||
| Q2 24 | — | $4.4B | ||
| Q1 24 | — | $4.4B |
| Q4 25 | $540.7M | $6.9B | ||
| Q3 25 | $505.8M | $6.8B | ||
| Q2 25 | $436.8M | $6.7B | ||
| Q1 25 | $418.6M | $6.7B | ||
| Q4 24 | $403.7M | $6.7B | ||
| Q3 24 | $405.9M | $6.8B | ||
| Q2 24 | $455.8M | $6.8B | ||
| Q1 24 | $452.0M | $7.0B |
| Q4 25 | $1.4B | $13.0B | ||
| Q3 25 | $1.4B | $13.1B | ||
| Q2 25 | $1.3B | $12.7B | ||
| Q1 25 | $1.3B | $12.6B | ||
| Q4 24 | $1.3B | $12.4B | ||
| Q3 24 | $1.3B | $12.4B | ||
| Q2 24 | $920.8M | $12.4B | ||
| Q1 24 | $914.5M | $12.7B |
| Q4 25 | — | 0.69× | ||
| Q3 25 | — | 0.72× | ||
| Q2 25 | — | 0.72× | ||
| Q1 25 | — | 0.69× | ||
| Q4 24 | — | 0.66× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 0.64× | ||
| Q1 24 | — | 0.63× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $30.4M | $203.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $29.1M | — |
| FCFマージンFCF / 売上 | 11.8% | — |
| 設備投資強度設備投資 / 売上 | 0.5% | — |
| キャッシュ転換率営業CF / 純利益 | 1.10× | 1.01× |
| 直近12ヶ月FCF直近4四半期 | $171.4M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $30.4M | $203.9M | ||
| Q3 25 | $44.1M | $218.7M | ||
| Q2 25 | $75.8M | $244.0M | ||
| Q1 25 | $35.0M | $161.0M | ||
| Q4 24 | $15.9M | $191.4M | ||
| Q3 24 | $12.5M | $227.6M | ||
| Q2 24 | $17.4M | $203.5M | ||
| Q1 24 | $18.3M | $167.8M |
| Q4 25 | $29.1M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $71.8M | — | ||
| Q1 25 | $32.5M | — | ||
| Q4 24 | $13.5M | — | ||
| Q3 24 | $7.7M | — | ||
| Q2 24 | $13.0M | — | ||
| Q1 24 | $13.7M | — |
| Q4 25 | 11.8% | — | ||
| Q3 25 | 16.7% | — | ||
| Q2 25 | 34.0% | — | ||
| Q1 25 | 16.5% | — | ||
| Q4 24 | 7.1% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 9.4% | — | ||
| Q1 24 | 10.0% | — |
| Q4 25 | 0.5% | — | ||
| Q3 25 | 2.7% | — | ||
| Q2 25 | 1.9% | — | ||
| Q1 25 | 1.3% | — | ||
| Q4 24 | 1.3% | — | ||
| Q3 24 | 3.2% | — | ||
| Q2 24 | 3.2% | — | ||
| Q1 24 | 3.3% | — |
| Q4 25 | 1.10× | 1.01× | ||
| Q3 25 | 1.66× | 2.00× | ||
| Q2 25 | 8.87× | 2.30× | ||
| Q1 25 | 2.23× | 1.47× | ||
| Q4 24 | — | 2.21× | ||
| Q3 24 | — | 2.24× | ||
| Q2 24 | — | 1.98× | ||
| Q1 24 | 1.00× | 1.53× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
REG
| Shopping Centers | $418.0M | 103% |
| Propertymanagementservices | $4.1M | 1% |
| Assetmanagementservices | $1.7M | 0% |
